In 2014, Tumeh and colleagues could show that pre-existing CD8+ T cells distinctly located at the invasive tumor front correlate with the expression of the immunosuppressive checkpoint molecules PD-1/PD-L1, predicting response to immunotherapy in patients suffering from malignant melanoma (3). The gene discussed is CD8A; the disease is neoplasm.